<DOC>
	<DOCNO>NCT01646554</DOCNO>
	<brief_summary>Patients present multiple innumerable liver metastases probably never come resection , however , others , include patient numerous multiple metastasis large metastasis , resection consider limited chemotherapy . There consensus backbone chemotherapy consist fluoropyrimidine + oxaliplatin . FOLFOX use previous EORTC study recommend . The addition target agent standard chemotherapy perioperative strategy mCRC might increase ORR R0 resectability , without significant increase toxicity , therefore translate well outcome . BOS2 ( EORTC 40091 ) design test hypothesis patient KRAS wold-type profile . It decide parallel design open label , randomize , multi-center , 2-arm phase II-III study time aim enrol KRAS mutate patient . Arm A : ( standard ) mFOLFOX6 + Surgery Arm B : ( experimental ) mFOLFOX6 + Aflibercept + Surgery</brief_summary>
	<brief_title>Efficacy FOLFOX Versus FOLFOX Plus Aflibercept K-ras Mutant Patients With Resectable Liver Metastases</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Histologically proven CRC 1 8 metachronous synchronous liver metastasis consider completely resectable Primary tumor ( liver metastasis ) CRC must KRAS status `` mutant '' Patients must undergo complete resection ( R0 ) primary tumor least 4 week randomization . Or patient synchronous metastasis primary tumor resect ( R0 ) time liver metastasis : patient nonobstructive primary tumor able receive preoperative chemotherapy ( 34 month ) surgery1 . Measurable hepatic disease RECIST version 1.1 Patients must 18 year old old A World Health Organization ( WHO ) performance status 0 1 Previous adjuvant chemotherapy primary CRC allow complete least 12 month inclusion study All following test do within 4 week prior randomization : Hematological status : neutrophil ( ANC ) = 1.5x10 9/L ; platelet = 100x10 9/L ; haemoglobin = 9g/dL Serum creatinine = 1.5 time upper limit normal ( ULN ) Proteinuria &lt; 2+ ( dipstick urinalysis ) =1g/24hour . Liver function : serum bilirubin = 1.5 x upper normal limit ( ULN ) , alkaline phosphatase &lt; 5xULN Magnesium â‰¥ low limit normal ( LLN ) Patients buffer range normal value +/ 5 % hematology +/ 10 % biochemistry acceptable . This apply Renal Function , include Creatinine . Women child bear potential ( WOCBP ) must negative serum ( urine ) pregnancy test within 14 day prior first dose study treatment . Patients childbearing / reproductive potential use adequate birth control measure , define investigator , study treatment period least 6 month last study treatment . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly . Female subject breast feed discontinue nursing prior first dose study treatment 6 month last study treatment . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Patient willing able comply protocol requirement Before patient registration/randomization , write informed consent must give accord ICH/GCP , national/local regulation . Evidence extrahepatic metastasis ( CRC ) Previous chemotherapy metastatic disease surgical treatment ( e.g . surgical resection radiofrequency ablation ) liver metastasis . Radiotherapy alone allow give pre post protocol treatment Previous exposure VEGF/VEGFR target therapy within last 12 month Major surgical procedure , open biopsy , significant traumatic injury within 4 week prior randomization Gilbert 's syndrome History myocardial infarction and/or stroke within 6 month prior randomization Uncontrolled hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) , history hypertensive crisis , hypertensive encephalopathy History evidence upon physical examination CNS metastasis Bowel obstruction Uncontrolled hypercalcemia Preexisting permanent neuropathy ( NCI grade = 2 ) Known allergy excipient study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Liver metastasis</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>KRAS mutate</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>Aflibercept</keyword>
	<keyword>Randomized</keyword>
	<keyword>Phase II-III</keyword>
	<keyword>Perioperative treatment</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Neo-adjuvant</keyword>
	<keyword>Surgery</keyword>
	<keyword>Progression Free Survival</keyword>
</DOC>